



NIH PUBLIC ACCESS

## Author Manuscript

*J Med Chem.* Author manuscript; available in PMC 2011 September 23.

Published in final edited form as:

*J Med Chem.* 2010 September 23; 53(18): 6699–6705. doi:10.1021/jm100846r.

## Antitumor Agents 280. Multidrug Resistance-Selective Desmosdumotin B Analogues

Kyoko Nakagawa-Goto<sup>a,\*</sup>, Po-Cheng Chang<sup>a,†</sup>, Chin-Yu Lai<sup>a,†</sup>, Hsin-Yi Hung<sup>a</sup>, Tzu-Hsuan Chen<sup>a</sup>, Pei-Chi Wu<sup>a</sup>, Hao Zhu<sup>b</sup>, Alexander Sedykh<sup>b</sup>, Kenneth F. Bastow<sup>c,\*</sup>, and Kuo-Hsiung Lee<sup>a,d,\*</sup>

<sup>a</sup>Natural Products Research Laboratories, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA

<sup>b</sup>Laboratory for Molecular Modeling, Division of Medicinal Chemistry and Natural Products, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599

<sup>c</sup>Division of Medicinal Chemistry & Natural Products, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA

<sup>d</sup>Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung, Taiwan

### Abstract

6,6,8-Triethyl-desmosdumotin B (**2**) was discovered as a MDR-selective flavonoid with significant *in vitro* anticancer activity against a multi-drug resistant (MDR) cell line (KB-VIN) but without activity against the parent cells (KB). Additional **2**-analogues were synthesized and evaluated to determine the effect of B-ring modifications on MDR-selectivity. Analogues with a B-ring Me (**3**) or Et (**4**) group had substantially increased MDR-selectivity. Three new disubstituted analogues, **35**, **37** and **49**, also had high collateral sensitivity (CS) indices of 273, 250 and 100, respectively. Furthermore, **2–4** also displayed MDR-selectivity in an MDR hepatoma-cell system. While **2–4** showed either no or very weak inhibition of cellular P-glycoprotein (P-gp) activity, they either activated or inhibited the actions of the first generation P-gp inhibitors verapamil or cyclosporin, respectively.

### Introduction

Incidences of drug resistance still present major and serious obstacles to the effective chemotherapeutic treatment of cancer, despite many efforts to overcome it.<sup>1,2</sup> Resistance to one drug often implies simultaneous resistance to structurally and mechanistically diverse anticancer drugs. This efflux phenotype, called multidrug resistance (MDR),<sup>3,4</sup> is in part mediated by the over-expression of plasma membrane transporters, such as P-glycoprotein (P-gp, MDR1 or ABCB1, localized at 7q21.1, a 170 kDa protein),<sup>5</sup> MDR-associated proteins (MRP1 or ABCC1, localized at 16p13.1, a 190 kDa protein, and MRP2),<sup>6</sup> or breast cancer resistant protein (BCRP or ABCG2, localized at 4q22, a 72 kDa protein).<sup>7–9</sup> These three kinds of proteins belong to the superfamily of ATP-binding-cassette (ABC)

\*Corresponding authors. K.N.G. Tel.: 919-843-6325, fax: 919-966-3893, goto@email.unc.edu, K.F.B. Tel.: 919-966-7633, fax: 919-966-0204, ken\_bastow@unc.edu, K.H.L. Tel.: 919-962-0066, fax: 919-966-3893, khlee@unc.edu.

†Contributed equally to the biological work

**Supporting Information Available.** Elemental analysis data for compounds **5–55**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

transporters.<sup>10</sup> The emergence of MDR pumps causes cancer drugs to be pumped out of the cell, thus reducing intracellular drug concentrations below cytotoxic levels. Because P-gp has broad substrate specificity, tumor cells that over-express P-gp show resistance to many classical and newer molecular-targeted antitumor drugs. The development of agents targeted toward MDR1 or MRP1 is greatly needed in order to improve anticancer chemotherapeutic strategies. MDR1/P-gp is a well-characterized efflux system and a major mediator of MDR.<sup>11–14</sup> Intrinsic or acquired over-expression of P-gp dramatically reduces drug response, at times to less than one-quarter, causing poor clinical outcomes following chemotherapy.<sup>15</sup>

To date, the major pharmacological approaches to overcome MDR have focused on inhibition of the pump function and/or down-regulation of pump over-expression.<sup>16–19</sup> Numerous pump inhibitors (or modulators) have been found, and are generally classified as first, second, or third generation chemosensitizers. Many second and third generation inhibitors, such as valspodar, zosuquidar, and tariquidar, are more potent and less toxic than first generation compounds like verapamil (VERAP) or cyclosporine A (CSA). Although some of these new generation compounds are still in clinical trials, the benefits of chemosensitization remain disappointing, in part because the modulator causes undesirable changes in drug pharmacokinetics.<sup>20</sup>

Flavonoids are the most widespread natural compounds produced in plants, and they exhibit diverse, important biological activities, including antioxidant, anticarcinogenic, antiinflammatory, antiproliferative, antiangiogenic and antiestrogenic effects.<sup>21</sup> Many reports have demonstrated that flavonoids can also interact with ABC transporters and some act as P-gp modulators.<sup>22–25</sup> We found that the flavonoid desmosdumotin B (**1**, Figure 1) exerted unique *in vitro* anticancer activity against a P-gp expressing MDR tumor cell line (KB-VIN, ED<sub>50</sub> = 2.0 µg/mL), resulting in a >20 fold index of selectivity over the drug sensitive KB parent cell line.<sup>26</sup> We also discovered that 6,8,8-triethyldesmosdumotin B (TEDB, **2**) and its 4'-methyl (**3**) and 4'-ethyl (**4**) analogues were significantly more potent and showed MDR-selectivity of >250.<sup>27</sup> In contrast, the related 6,8,8-tripropyl as well as 6,8-diethyl compounds were less optimized for MDR-selectivity.

The hypersensitivity of drug-resistance was first reported using *Escherichia coli* in 1952, and the phenomenon was termed “collateral sensitivity” (CS).<sup>28</sup> A significant CS agent should show at least two-fold greater activity against the MDR line than the parental line. Recently, Hall *et al* published a review concerning CS, and argued that exploiting CS agents, which especially kill MDR cancer cells, is an exciting challenge and opportunity for new drug discovery as well as clinical development.<sup>29</sup> A thiosemicarbazone derivative (NSC73306) was discovered through the US National Cancer Institute (NCI) anticancer drug screen as a drug lead for targeting MDR tumor cell populations, and several derivatives showed improved MDR-selectivity.<sup>30–31</sup> While it was toxic toward a diverse panel of Pgp-expressing tumor cell lines, the CS index was only 7.3-fold at best. Thus, the MDR-selectivity of **2** and its known active analogues is substantially better, but many questions remain about these unique flavonoids. In this report, we address some critical issues by looking at effects on P-gp function, *in vitro* anticancer activity using a second drug-selected (hepatoma) MDR-cell system, and general mode and mechanism of cytotoxicity. We also explored structure-activity relationship (SAR) results for this unique compound class with major focus on the modification of B-ring substituents.

## Chemistry

Generally, analogues **5–55** were synthesized through a three-step sequence, Claisen-Schmidt condensation of **5626** with a substituted benzaldehyde (ArCHO), cyclization to form the pyranone A-ring, and C-7 demethylation with BBr<sub>3</sub> as shown in Scheme 1. Because the C-7

methoxy group was removed faster than a phenyl B-ring methoxy group, treatment with  $\text{BBr}_3$  was carried out at a low temperature to retain the latter group. Analogues **10** and **44–46**, which contain hydroxy groups, were obtained from the related methoxy (for **10**, **44**, and **45**) or benzyloxy (for **46**) phenylaldehydes. The methyl and benzyl ethers were cleaved at the final stage to provide the alcohols. 4'-Bromomethylphenyl analogue **18** was produced by  $\text{BBr}_3$  treatment when 4'-(methoxymethyl)benzaldehyde, derived from commercially available [4-(dimethoxymethyl)phenyl]methanol, was used as the ArCHO. Analogues **2–4** were synthesized previously.

## Results and Discussion

All synthesized **2**-analogues were evaluated *in vitro* against two human tumor cell lines, the KB-VIN cell line, an MDR P-gp expressing cloned subline stepwise selected using vincristine, and its parental non-MDR KB cell line. The cytotoxic activity data including KB/KB-VIN sensitivity are listed in Tables 1 (mono-substituted phenyl B-ring) and 2 (multi-substituted phenyl B-ring). Except for **10**, **26**, and **53**, which showed no MDR selectivity, all **2**-analogues demonstrated greater cytotoxicity against KB-VIN than KB, resulting in CS indices of over 2.0. Regarding the mono-substituted B-ring analogues (Table 1), 4'-Me (**3**) and 4'-Et (**4**) compounds inhibited KB-VIN cell growth most strongly with  $\text{ED}_{50}$  values of 0.08 and 0.07  $\mu\text{M}$ , and CS indices of 460 and 320, respectively. Other compounds with significant KB-VIN inhibition ( $\text{ED}_{50} < 2.0 \mu\text{M}$ ) had the following rank order: **11** (4'-OMe,  $\text{ED}_{50} = 0.68 \mu\text{M}$ ), **6** (4'-iPr,  $\text{ED}_{50} = 1.08 \mu\text{M}$ ), **22** (3'-OMe,  $\text{ED}_{50} = 1.22 \mu\text{M}$ ), **15** (4'-SMe,  $\text{ED}_{50} = 1.38 \mu\text{M}$ ), and **17** (4'-F,  $\text{ED}_{50} = 1.85 \mu\text{M}$ ). Among of 4'-substituted analogues, **2–19**, compounds with a longer side chain (over three carbons), OH, CHO, and  $\text{CH}_2\text{Br}$  at the 4'-position or 2'- $\text{CF}_3$  lost potency against KB-VIN and the order of substituents by decreasing selectivity was as follows: Me, Et > H  $\gg$  SMe, OMe > F > OEt > OPr >  $\text{CF}_3$ , etc.

Compounds **20–28** carry a single substitution on the C2'- or C3'-position of the benzene ring. All of them, except **26**, exhibited some degree of selectivity; however, they showed lower activity against KB-VIN compared to the parent unsubstituted compound.

Regarding multi-substituted B-ring analogues (Table 2), except for **54**, all analogues showed potent cytotoxicity against KB-VIN. Among them, **35**, **37**, and **49** had notable CS indices of 273, 250, and 100, respectively. Multiple substitutions on the benzene ring of compounds **29–55** demonstrated that, in general, increased selectivity and activity towards KB-VIN is afforded by small hydrophobic groups in C4'- and C3'-positions. The decreasing rank order for selectivity was as follows: 3-Me-4-OMe (**35**); 3'-F-4'-OMe (**37**) > 3',5'-diMe (**49**) > 3',4'-diMe (**30**) > 3'-Me-4'-F (**55**) > 2',3'-diMe-4'-OMe (**39**), > 3'-Cl-4'-Me (**31**) = 3'-Cl-4'-OMe (**38**) > 2'-F-5'-Me (**54**) > 3',5'-diOMe (**52**) > 3'-F-4'-Me (**32**) > 2',3'-diOMe (**50**), etc. These results indicate that substitutions on C3' and C4' significantly contribute to the KB/KB-VIN sensitivity. Especially, C3'-substitution was the most important for the activity towards KB-VIN (see, for instance, the change in activity for the pairs of compounds **29** and **30**, **34** and **35**, **39** and **40**, **48** and **49**). It is unclear to what extent the methoxy and halogen groups acting as hydrogen bond acceptors contribute to the observed changes.

The previously synthesized **2–4** were also evaluated *in vitro* against a human hepatoma MDR cell system, and the data are shown in Table 3. Hep3B-VIN cells are P-gp-expressing and selected using vincristine from the parent non-MDR Hep3B cell line. The CS indices measured for **2–4** were 30, 21, and 8.5, respectively, which are lower than values against KB-VIN cells. Interestingly, the order of potency was changed to **3** ( $\text{GI}_{50} 0.35 \mu\text{M}$ ) > **4** ( $\text{GI}_{50} 0.72 \mu\text{M}$ ) > **2** ( $\text{GI}_{50} 1.57 \mu\text{M}$ ), compared with that against KB-VIN [**4** ( $\text{ED}_{50} 0.068 \mu\text{M}$ ) = **3** ( $\text{ED}_{50} 0.085 \mu\text{M}$ ) > **2** ( $\text{ED}_{50} 1.07 \mu\text{M}$ )] (Tables 1 and 3). However, it is significant

that all three compounds displayed selective *in vitro* anticancer action against the hepatoma-derived MDR cell line, because this finding shows that the activity is not peculiar to a single MDR-cell line.

The effects of **2–4** on P-gp function in KB-VIN (MDR) cells was also investigated as shown in Figure 2. Drug pumping activity and inhibition of P-gp were measured using the standard calcein-AM loading assay as described under methods. Figure 2A shows the effects of treatment **2**, **3** or **4** compared with those of first generation competitive inhibitors VERAP and CSA. The data show that the latter two prototype P-gp inhibitors stimulated calcein-AM influx, while compounds **3** and **4** inhibited the pump but only very weakly over the concentration range tested (as compared to the action of VERAP and CSA shown in Figure 2A), and compound **2** was inactive. These results indicated that **2** had no detectable effect on P-gp function in KB-VIN cells, while **3** and **4** were weak inhibitors, but only at concentrations much higher than those that induced CS. The effects of co-treatment with **2**, **3**, or **4** and a fixed concentration of an active inhibitor (2.5 µg/ml VERAP or 4 µg/mL CSA) are shown in Figures 2B–D respectively. Interestingly, inhibition of P-gp activity was influenced by co-treatment with each MDR-selective compound and the magnitude and type of interaction depended on the identity of compound and P-glycoprotein inhibitor, respectively. All three compounds stimulated calcein-AM influx upon co-treatment with VERAP, but had the opposite effect when co-treated with CSA. The activation of VERAP inhibition of P-gp was clearly concentration-dependent over the range tested, while the responses were dose-limiting and more complicated for CSA with compound **3** or **4**. Compound **2** possessed the weakest activity, and compounds **3** and **4** were substantially more potent (compare accumulation of intracellular fluorescence between Figures 2B–D). A direct correlation between P-gp functional effects (Figures 2B–D) and *in vitro* anticancer activity against KB-VIN cells (Table 1) was not observed, although the rank-order of the three compounds' activity in both assays is apparent. In conclusion, compounds **2**, **3** and **4** are not potent P-gp inhibitors (Figure 2A), although they can clearly influence interaction of the enzyme with substrates/inhibitors in MDR cells.

As shown in Figure 3, compound **2** was evaluated against KB-VIN cells together with non-toxic concentrations of P-gp modulators VERAP or the allosteric inhibitor flupenthixol. Co-treatment of **2** with VERAP or flupenthixol (Z-isomer) partially reversed the *in vitro* anticancer activity of **2**, showing that the MDR-selectivity was dependent in-part on P-gp function and consistent with the effect on P-gp activity measured using the co-incubation treatment protocol. Similar results showing partial reversal of **3** and **4** MDR-selectivity were observed (data not shown). Further analysis using suitable probe analogues will be needed to determine if the agents interact directly with P-gp and to map possible interaction domains.

Cell death induced by **2** and effect of co-treatment with VERAP are shown in Figure 4. The effect of **2** on apoptosis in KB-VIN cells was measured using a Cell Death Detection ELISA<sup>PLUS</sup> kit (Roche Diagnostics, Mannheim, Germany). As shown in Figure 4A, one-day treatment induced a dose-dependent increase in adsorbance associated with histone-associated-DNA-fragments in the cytoplasm. The half-maximal effect occurred between 1–2 µg/ml of **2**, consistent with *in vitro* anticancer activity (Table 1). Co-treatment with VERAP reversed the **2**-induced DNA fragmentation. At one day post-treatment, immuno-blot analysis clearly showed pro-caspase-3 cleavage, which again was prevented by VERAP co-treatment (Fig 4B). These data demonstrate that **2** can induce classical apoptosis in KB-VIN cells, and P-gp activity is implicated and required due to the antagonistic action of the pump inhibitor.

Whether these effects are mediated via direct interaction with the P-gp enzyme (perhaps at an allosteric site resulting in conformational change) or via indirect action (by affecting

membrane properties and permeation of substrate/inhibitors) remain to be elucidated. However, the current data are consistent with **2–4** being novel P-gp actives and suggest that elucidation of the relationship between the MDR phenotype and the potent and selective in vitro anticancer action is warranted and will be worthwhile.

## Conclusions

In summary, all analogues demonstrated greater cytotoxicity against KB-VIN than KB, resulting in CS indices of over 2.0, except for **10**, **26**, and **53**. Among newly synthesized analogues, **35**, **37**, and **49** displayed potent in vitro anticancer activity against KB-VIN, with CS-ratios of 273, 250 and 100, respectively. These results indicated that substitutions on C3' and C4' significantly contribute to the KB/KB-VIN sensitivity.

Previously synthesized **2–4** also showed MDR selectivity against the drug-resistant human hepatoma cell line Hep3B-VIN. While analogues **2–4** did not inhibit or only weakly inhibited drug efflux P-gp pump activity, they either activated or inhibited the drug efflux pump activity of prototype P-gp inhibitors VERAP and CSA, respectively. The flavonoid compounds clearly influenced interaction of the enzyme with substrates/inhibitors in MDR cells, although they did not inhibit P-gp. The MDR selectivity was reversed by co-treatment with diverse P-gp inhibitors, such as VERAP or flupenthixol, suggesting dependence on efflux pump activity, and **2**-treatment induced apoptosis in KB-VIN cells.

Because of the unique bioactivity of this flavonoid series against P-gp over-expressing tumor cell lines, we plan to explore detailed mechanism of action and preclinical application studies on their potential as new cancer drugs.

## Experimental Section

### Chemistry. General

All chemicals and solvents were used as purchased. All melting points were measured on a Fisher-Johns melting point apparatus without correction.  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded on a Varian Gemini 2000 (300 MHz) NMR spectrometer with TMS as the internal standard. All chemical shifts are reported in ppm. NMR spectra were referenced to the residual solvent peak; chemical shifts  $\delta$  in ppm; apparent scalar coupling constants  $J$  in Hz. Mass spectroscopic data were obtained on a TRIO 1000 mass spectrometer. Analytical thin-layer chromatography (TLC) was carried out on Merck precoated aluminum silica gel sheets (Kieselgel 60 F-254). All target compounds were characterized by  $^1\text{H}$ -NMR, MS, and elemental analyses. The purities of >95% were determined by  $^1\text{H}$ -NMR and elemental analyses.

### General synthetic procedures for 1-analogues

The aryl-substituted intermediate compound (**57**) was dissolved in 0.1% conc  $\text{H}_2\text{SO}_4$  in DMSO, then  $\text{I}_2$  (0.1 eq. mol) was added and the reaction mixture heated at 90–95 °C for 1 h. The reaction mixture was quenched with ice-cold aq 10%  $\text{Na}_2\text{S}_2\text{O}_3$  and extracted with EtOAc. The extract was washed with brine, dried over  $\text{Na}_2\text{SO}_4$  and concentrated *in vacuo*. The residue was chromatographed on silica gel eluting with EtOAc–hexane (1:4 to 1:2, v/v) to afford the 7-methoxy substituted analogue (**58**), which was dissolved in anhydrous  $\text{CH}_2\text{Cl}_2$ . The mixture was cooled to –78 °C.  $\text{BBr}_3$  (3 eq. mol, 1.0 M solution in  $\text{CH}_2\text{Cl}_2$ ) was added to the solution, which was warmed to 0 °C spontaneously and stirred until the starting material was consumed. After addition of water, the reaction mixture was extracted three times with  $\text{CH}_2\text{Cl}_2$ . The extracts were combined, washed with brine, dried over  $\text{Na}_2\text{SO}_4$  and concentrated *in vacuo*. The residue was chromatographed on silica gel eluting with EtOAc–hexane (1:4) to obtain the target compound (**5–55**). The physical data of

representative compounds, **5** for 4'-substituted analog, **20** for 3'-substituted analog, **27** for 2'-substituted analog, **29** for 2',4'-disubstituted analog, **35** for 3',4'-disubstituted analog, and **49** for 3',5'-disubstituted analog are described below. Data for other compounds are in the supporting information.

#### 4'-Propyl-6,8,8-triethyl-desmosdumotin B (**5**)

Pale yellow prisms, mp 169–170 °C (EtOAc-Hexane). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 13.14 (s, 1H, 5-OH), 7.72 (d, 2H, *J* = 8.2 Hz, Ar-*H*), 7.36 (d, 2H, *J* = 8.2 Hz, Ar-*H*), 6.87 (s, 1H, 3-*H*), 2.69 (t, 2H, *J* = 7.3 Hz, 4'-CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 2.45 (q, 2H, *J* = 7.3 Hz, 6-CH<sub>2</sub>CH<sub>3</sub>), 2.33-2.19 (m, 2H, 8-CH<sub>2</sub>CH<sub>3</sub>), 2.07-1.92 (m, 2H, 8-CH<sub>2</sub>CH<sub>3</sub>), 1.76-1.62 (m, 2H, 4'-CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 1.04 (t, 3H, *J* = 7.4 Hz, 6-CH<sub>2</sub>CH<sub>3</sub>), 0.97 (t, 3H, *J* = 7.3 Hz, 4'-CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 0.67 (t, 6H, *J* = 7.3 Hz, 8-CH<sub>2</sub>CH<sub>3</sub>). MS (ESI<sup>+</sup>) *m/z*: 381 (M<sup>+</sup>+1). Anal. (C<sub>24</sub>H<sub>28</sub>O<sub>4</sub>) C, H, O.

#### 3'-Methyl-6,8,8-triethyl-desmosdumotin B (**20**)

Pale yellow prisms, mp 109–110 °C (EtOAc-hexane). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 13.09 (s, 1H, 5-OH), 7.64-7.56 (m, 2H, Ar-*H*), 7.49-7.39 (m, 1H, Ar-*H*), 6.89 (s, 1H, 3-*H*), 2.48 (s, 3H, 3'-CH<sub>3</sub>), 2.46 (q, 2H, *J* = 7.4 Hz, 6-CH<sub>2</sub>CH<sub>3</sub>), 2.34-2.20 (m, 2H, 8-CH<sub>2</sub>CH<sub>3</sub>), 2.08-1.93 (m, 2H, 8-CH<sub>2</sub>CH<sub>3</sub>), 1.04 (t, 3H, *J* = 7.4 Hz, 6-CH<sub>2</sub>CH<sub>3</sub>), 0.67 (t, 6H, *J* = 7.4 Hz, 8-CH<sub>2</sub>CH<sub>3</sub>). MS (ESI<sup>+</sup>) *m/z*: 353 (M<sup>+</sup>+1). Anal. (C<sub>22</sub>H<sub>24</sub>O<sub>4</sub>) C, H, O.

#### 2'-Methoxy-6,8,8-triethyl-desmosdumotin B (**27**)

Pale yellow prisms, mp 139–140 °C (EtOAc-hexane). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 13.24 (s, 1H, 5-OH), 7.70 (dd, 1H, *J* = 8.0, 1.6 Hz, 6'-*H*), 7.55 (ddd, 1H, *J* = 8.5, 7.4, 1.6 Hz, 4'-*H*), 7.23 (s, 1H, 3-*H*), 7.13 (dd, 1H, *J* = 8.0, 7.4 Hz, 5'-*H*), 7.08 (d, 1H, *J* = 8.5 Hz, 3'-*H*), 2.46 (q, 2H, *J* = 7.4 Hz, 6-CH<sub>2</sub>CH<sub>3</sub>), 2.30-2.16 (m, 2H, 8-CH<sub>2</sub>CH<sub>3</sub>), 2.04-1.90 (m, 2H, 8-CH<sub>2</sub>CH<sub>3</sub>), 1.04 (t, 3H, *J* = 7.4 Hz, 6-CH<sub>2</sub>CH<sub>3</sub>), 0.67 (t, 6H, *J* = 7.4 Hz, 8-CH<sub>2</sub>CH<sub>3</sub>). MS (ESI<sup>+</sup>) *m/z*: 369 (M<sup>+</sup>+1). Anal. (C<sub>22</sub>H<sub>24</sub>O<sub>5</sub>) C, H, O.

#### 2',4'-Dimethyl-6,8,8-triethyl-desmosdumotin B (**29**)

Pale yellow prisms, mp 129–130 °C (EtOAc-hexane). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 13.14 (s, 1H, 5-OH), 7.35 (d, 1H, *J* = 8.5 Hz, 6'-*H*), 7.21-7.14 (m, 2H, 3' and 5'-*H*), 6.59 (s, 1H, 3-*H*), 2.1-2.38 (m, 2H, 6-CH<sub>2</sub>CH<sub>3</sub>), 2.43 (s, 3H, 2' or 3'-CH<sub>3</sub>), 2.41 (s, 3H, 2' or 3'-CH<sub>3</sub>), 2.28-2.12 (m, 2H, 8-CH<sub>2</sub>CH<sub>3</sub>), 1.98-1.82 (m, 2H, 8-CH<sub>2</sub>CH<sub>3</sub>), 1.04 (t, 3H, *J* = 7.4 Hz, 6-CH<sub>2</sub>CH<sub>3</sub>), 0.65 (t, 6H, *J* = 7.4 Hz, 8-CH<sub>2</sub>CH<sub>3</sub>). MS (ESI<sup>+</sup>) *m/z*: 389 (M<sup>+</sup>+Na). Anal. (C<sub>23</sub>H<sub>26</sub>O<sub>4</sub>) C, H, O.

#### 4'-Methoxy-3'-methyl-6,8,8-triethyl-desmosdumotin B (**35**)

Pale yellow prisms, mp 169–170 °C (EtOAc-hexane). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 13.26 (s, 1H, 5-OH), 7.65 (dd, 1H, *J* = 8.2, 2.5 Hz, 6'-*H*), 7.55 (d, 1H, *J* = 2.5 Hz, 2'-*H*), 6.96 (d, 1H, *J* = 8.2 Hz, 5'-*H*), 6.79 (s, 1H, 3-*H*), 3.93 (s, 3H, 4'-OCH<sub>3</sub>), 2.45 (q, 2H, *J* = 7.3 Hz, 6-CH<sub>2</sub>CH<sub>3</sub>), 2.30 (s, 3H, 3'-CH<sub>3</sub>), 2.33-2.18 (m, 2H, 6- or 8-CH<sub>2</sub>CH<sub>3</sub>), 2.06-1.92 (m, 2H, 6- or 8-CH<sub>2</sub>CH<sub>3</sub>), 1.04 (t, 3H, *J* = 7.3 Hz, 6-CH<sub>2</sub>CH<sub>3</sub>), 0.67 (t, 3H, *J* = 7.3 Hz, 8-CH<sub>2</sub>CH<sub>3</sub>). MS (ESI<sup>+</sup>) *m/z*: 383 (M<sup>+</sup>+1). Anal. (C<sub>23</sub>H<sub>26</sub>O<sub>5</sub>) C, H, O.

#### 3',5'-Dimethyl-6,8,8-triethyl-desmosdumotin B (**49**)

Pale yellow prisms, mp 138–139 °C (EtOAc-hexane). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 13.13 (s, 1H, 5-OH), 7.38 (br s, 2H, Ar-*H*), 7.24 (br s, 1H, Ar-*H*), 6.87 (s, 1H, 3-*H*), 3.95 and 3.89 (s, 3H each, 2' and 3'-OCH<sub>3</sub>), 2.45 (q, 2H, *J* = 7.3 Hz, 6-CH<sub>2</sub>CH<sub>3</sub>), 2.43 (s, 6H, 3' and 5'-CH<sub>3</sub>), 2.32-2.20 (m, 2H, 8-CH<sub>2</sub>CH<sub>3</sub>), 2.06-1.92 (m, 2H, 8-CH<sub>2</sub>CH<sub>3</sub>), 1.04 (t, 3H, *J* = 7.4 Hz, 6-CH<sub>2</sub>CH<sub>3</sub>), 0.67 (t, 6H, *J* = 7.3 Hz, 8-CH<sub>2</sub>CH<sub>3</sub>). MS (ESI<sup>+</sup>) *m/z*: 399 (M<sup>+</sup>+Na). Anal. (C<sub>23</sub>H<sub>26</sub>O<sub>4</sub>) C, H, O.

## Cytotoxic Activity Assay

All stock cultures were grown in T-25 flasks. Freshly trypsinized cell suspensions were seeded in 96-well microtiter plates at densities of 1500–7500 cells per well with compounds added from DMSO-diluted stock. After three days in culture, attached cells were fixed with cold 50% trichloroacetic acid and then stained with 0.4% sulforhodamine B. The absorbency at 562 nm was measured using a microplate reader after solubilizing the bound dye. The mean ED<sub>50</sub> is the concentration of agent that reduces cell growth by 50% under the experimental conditions and is the average from at least three independent determinations that were reproducible and statistically significant. For the VERAP reversal experiments, cells were co-treated with VERAP (1 µg/mL). Control experiments showed this concentration had no effect on the replication of KB-VIN cells. The following human tumor cell lines were used in the assay: KB (nasopharyngeal carcinoma) and KB-VIN (vincristine-resistant KB subline). All cell lines were obtained from Lineberger Cancer Center (UNC-CH) or from ATCC (Rockville, MD), except KB-VIN, which was a generous gift of Professor Y.-C. Cheng, Yale University. Cells were cultured in RPMI-1640 medium supplemented with 25 mM HEPES, 0.25% sodium bicarbonate, 10% fetal bovine serum, and 100 µg/mL kanamycin.

## Detection of P-gp activity (calcein-AM loading assay)

Calcein-AM is a probe substrate of P-gp and is converted into a fluorescent derivative via cellular enzymes. MDR cells give low intrinsic fluorescent signals with this probe substrate, unless P-gp is inhibited and then relative fluorescence will increase (see Figure 2-A for effects of classical P-gp inhibitors). For the assay, 10,000 KB-VIN (MDR) cells per well were seeded into 96-well plates with RPMI-1640 medium containing 5% FBS and incubated in a humidified incubator for adhesion and growth. After 24 h incubation, the indicated concentrations of test compounds were added into wells for 30 min at 37°C. Medium was aspirated then replaced with fresh medium containing 1 µM calcein-AM and indicated compounds. After continuing culture for 30 min at 37 °C in the dark, medium was removed and the plates were washed gently and quickly with cold isotonic (PBS) buffer in the dark. Cells were lysed using hypotonic Tris-HCl buffer, and fluorescence was detected using an ELISA reader (Ex. 494 nm, Em. 517 nm.). Composite data obtained from two or more independent experiments were analyzed using Prism™ (Graphpad Software, San Diego, CA).

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Abbreviations

<b>ABC</b>	ATP-binding-cassette
<b>ArCHO</b>	substituted benzaldehyde
<b>BCRP</b>	breast cancer resistant protein
<b>CS</b>	collateral sensitivity
<b>CSA</b>	cyclosporine A
<b>MDR</b>	multidrug resistance/resistant
<b>NCI</b>	National Cancer Institute
<b>P-gp</b>	P-glycoprotein

<b>SAR</b>	structure-activity relationship
<b>TEDB</b>	6,8,8-triethyldesmosdumotin B
<b>VERAP</b>	verapamil

## Acknowledgments


This study was supported by grant CA-17625 from the National Cancer Institute, NIH, awarded to K. H. L and by a grant from the University Research Council, awarded to K.N.G.

## References


1. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. *Cell. Mol. Life Sci.* 2008; 65:3145–3167. [PubMed: 18581055]
2. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. *Curr. Med. Chem.* 2006; 13:1859–1876. [PubMed: 16842198]
3. Fojo T, Bates S. Strategies for reversing drug resistance. *Oncogene.* 2003; 22:7512–7523. [PubMed: 14576855]
4. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. *Cancer Sci.* 2003; 94:15–21. [PubMed: 12708468]
5. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. *Annu. Rev. Biochem.* 1989; 58:137–171. [PubMed: 2570548]
6. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science.* 1992; 258:1650–1654. [PubMed: 1360704]
7. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. *Proc. Natl. Acad. Sci. USA.* 1998; 95:15665–15670. [PubMed: 9861027]
8. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. *Cancer Res.* 1998; 58:5337–5339. [PubMed: 9850061]
9. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. *Cancer Res.* 1999; 59:8–13. [PubMed: 9892175]
10. Recent review for ABC transporters: a) Eckford PDW, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. *Chem. Rev.* 2009; 109:2989–3011. [PubMed: 19583429] b) Sharom FJ. ABC multidrug transporters: Structure, function and role in chemoresistance. *Future Medicine.* 2008; 9:105–127.
11. Crowley E, Callaghan R. Multidrug efflux pumps: drug binding-gates or cavity? *FEBS.* 2010; 277:530–539.
12. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. *Science.* 2009; 323:1718–1722. [PubMed: 19325113]
13. Kimura Y, Morita S, Matsuo M, Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. *Cancer Sci.* 2007; 98:1303–1310. [PubMed: 17608770]
14. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. *Oncogene.* 2003; 22:7468–7485. [PubMed: 14576852]
15. Modok S, Mellor HR, Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. *Curr. Opin. Pharm.* 2006; 6:350–354.
16. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. *Curr. Pharm. Design.* 2006; 12:273–286.



17. Avendaño C, Menéndez JC. Recent advance in multidrug resistance modulators. *Med. Chem. Rev.* 2004; 1:419–444.
18. Kawase M, Motohashi N. New multidrug resistance reversal agents. *Curr. Drug Targets.* 2003; 4:31–43. [PubMed: 12528988]
19. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. *Curr. Drug Targets.* 2000; 1:85–99. [PubMed: 11475537]
20. Coley HM. Overcoming multidrug resistance in cancer: clinical studies of P-glycoprotein inhibitors. *Methods Mol. Biol.* 2010; 549:341–358. [PubMed: 19949931]
21. Havsteen BH. The biochemistry and medical significance of the flavonoids. *Pharmacol. Ther.* 2002; 96:67–202. [PubMed: 12453566]
22. Alvarez AI, Real R, Pérez M, Mendoza G, Prieto JG, Merino G. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. *J. Pharm. Sci.* 2010; 99:598–617. [PubMed: 19544374]
23. Bansal T, Jagdil M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. *J. Pharm. Pharmaceut. Sci.* 2009; 12:46–78.
24. Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. *Life Sciences.* 2006; 78:2116–2130. [PubMed: 16455109]
25. Boumendjel A, Di Pietro A, Dumontet C, Barron D. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. *Med. Res. Rev.* 2002; 22:512–529. [PubMed: 12210557]
26. Nakagawa-Goto K, Bastow KF, Wu J-H, Tokuda H, Lee KH. Total synthesis and bioactivity of unique flavone desmosdumotin B and its analogs. *Bioorg. Med. Chem. Lett.* 2005; 15:3016–3019. [PubMed: 15913998]
27. Nakagawa-Goto K, Bastow KF, Cgen TH, Morris-Natschke SL, Lee KH. Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity. *J. Med. Chem.* 2009; 51:3297–3303. [PubMed: 18473435]
28. Szybalski W, Bryson V. Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of *Escherichia coli* to fifteen antibiotics. *J. Bacteriol.* 1952; 64:489–499. [PubMed: 12999676]
29. Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. *Trends in Pharmacological Sciences.* 2009; 30:546–556. [PubMed: 19762091] (Note: The structure of desmosdumotin analog **11** in Figure 3 is missing a triethyl group on A-ring; it should be the same as **3** in this article)
30. Ludwig JA, Szakács G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, Caplen NJ, Fales HM, Ambudkar SV, Weinstein JN, Gottesman MM. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. *Cancer Res.* 2006; 66:4808–4815. [PubMed: 16651436]
31. Hall MD, Salam NK, Hellowell JL, Fales HM, Kensler CB, Ludwig JA, Szakács G, Hibbs DE, Gottesman MM. Synthesis, activity, and pharmacophore development for isatin- $\beta$ -thiosemicarbazones with selective activity toward multidrug-resistant cells. *J. Med. Chem.* 2009; 52:3191–3204. [PubMed: 19397322]



**1:** Desmodumotin B







**2:** 6,8,8-Triethyl-desmodumotin B  
(TEDB, R = H)

**3:** R = 4'-Me


**4:** R = 4'-Et

Figure 1.







**Figure 2.**  
Effect on P-gp function in KB-VIN cells



**Figure 3.** Chemoprotection of **2** by MDR-1 modulators in KB-VIN cells. Co-treatment with non-toxic concentrations of VERAP or flupenthixol partially reversed *in vitro* anticancer activity of **2** against MDR-1 cell line (measured by use of the anionic protein dye sulforhodamine-B (SRB)). These results show that a competitive substrate-type inhibitor (VERAP) and an allosteric-type pump inhibitor (Flupent) can negate MDR-selective cytotoxicity.




**Figure 4.**  
The effect of **2** on apoptosis in KB-VIN cells was measured using a Cell Death Detection ELISA<sup>PLUS</sup> kit (Roche Diagnostics, Mannheim, Germany).




Reagents: a) 50% KOH, EtOH, ArCHO, rt, b) I<sub>2</sub>, DMSO, H<sub>2</sub>SO<sub>4</sub>; c) BBr<sub>3</sub>


ArCHO




R = Me Et Pr Pr Bu tBu CF<sub>3</sub> OMe OEt OPr  
OCF<sub>3</sub> SMe Br F CH<sub>2</sub>OMe CH(OEt)<sub>2</sub>




R = Me CF<sub>3</sub> OMe OCF<sub>3</sub> F



R = Me CF<sub>3</sub> OMe F



R = Me R = 2-Me 3-Me 3-C 3-F 2 5-d Me  
R = OMe R = 2-Me 3-Me 3-OMe 3-C 3-F 2 3-d Me 2 5-d Me  
2 3-OMe 3 5-OMe 3-C-5-OMe  
R = OBz R-3 5-d Me



R = 2 3-d Me 2 5-d Me 3 5-d Me 2 3-d OMe 2 6-d OMe 3 5-d OMe  
2 3-d OEt 3-OMe-4-OEt 2-F-5-Me 4-F-3-Me

**Scheme 1.**  
Syntheses of TEDB Analogues

Table 1

Activity of **3-29** (mono-substituted phenyl B-ring) against KB and KB-VIN

	R				ED <sub>50</sub> (μM) <sup>a</sup>		Selectivity KB/KB-VIN
	2'	3'	4'	5'	KB	KB-VIN	
<b>2</b>					>236.7	1.07	>221
<b>3</b>			Me		39.2	0.08	460
<b>4</b>			Et		21.9	0.07	320
<b>5</b>			Pr		>53	12.16	>4
<b>6</b>			iPr		8.13	1.08	3
<b>7</b>			Bu		110.7	36.95	3.0
<b>8</b>			tBu		29.3	17.4	2
<b>9</b>			CF <sub>3</sub>		35.7	10.35	3.5
<b>10</b>			OH		20.6	20.6	1
<b>11</b>			OMe		17.7	0.68	26
<b>12</b>			OEt		>52.4	7.54	>7
<b>13</b>			OPr		>50.5	29.17	>2
<b>14</b>			OCF <sub>3</sub>		36.49	9.95	4
<b>15</b>			SMe		>52.1	1.38	>38
<b>16</b>			Br		>48.1	15.70	3
<b>17</b>			F		33.0	1.85	18
<b>18</b>			CH <sub>2</sub> Br		>46.5	27.91	>2
<b>19</b>			CH <sub>2</sub> OMe		>52.4	3.40	15
<b>20</b>		Me			49.7	3.69	14
<b>21</b>		CF <sub>3</sub>			35.7	5.42	6.6
<b>22</b>		OMe			13.3	1.22	11
<b>23</b>		OCF <sub>3</sub>			>47.4	9.95	>5
<b>24</b>		F			>56.2	3.09	>18
<b>25</b>	Me				40.9	2.41	17
<b>26</b>	CF <sub>3</sub>				45.6	43.10	1



	<b>R</b>				<b>ED<sub>50</sub> (μM)<sup>a</sup></b>		<b>Selectivity</b>
	<b>2'</b>	<b>3'</b>	<b>4'</b>	<b>5'</b>	<b>KB</b>	<b>KB-VIN</b>	<b>KB/KB-VIN</b>
<b>27</b>	OMe				40.8	3.26	13
<b>28</b>	F				>56.2	3.93	>14

<sup>a</sup> Cytotoxicity as ED<sub>50</sub> values for each cell line, the concentration of compound that caused 50% reduction in absorbance at 562 nm relative to untreated cells using the sulforhodamine B assay.

Table 2

Activity of **30-56** (multi-substituted phenyl B-ring) against KB and KB-VIN

	R				ED <sub>50</sub> (μM) <sup>a</sup>		Selectivity KB/KB-VIN
	2'	3'	4'	5'	KB	KB-VIN	
29	Me		Me		41.2	8.52	5
30		Me	Me		35.5	0.71	50
31		Cl	Me		39.0	2.15	18
32		F	Me		28.1	2.95	10
33	Me		Me	Me	8.2	4.37	2
34	Me		OMe		20.9	2.62	8
35		Me	OMe		28.5	0.10	273
36		OMe	OMe		14.7	1.00	15
37		F	OMe		26.7	0.10	250
38		Cl	OMe		24.9	1.37	18
39	Me	Me	OMe		5.43	0.28	20
40	Me		OMe	Me	36.6	7.58	5
41	OMe	OMe	OMe		9.4	1.57	6
42		OMe	OMe	OMe	46.7	5.6	8
43		Cl	OMe	OMe	21.8	8.40	3
44		OH	OH		10.0	5.41	2
45	Me	Me	OH		6.5	2.75	2
46		Me	OH	Me	18.3	8.90	2
47	Me	Me			3.1	0.85	4
48	Me			Me	14.5	3.41	4
49		Me		Me	45.5	0.45	100
50	OMe	OMe			35.2	4.02	9
51	OMe			OMe	8.8	2.51	4
52		OMe		OMe	45.2	3.27	14
53	OEt	OEt			44.6	31.69	1.4

	R					ED <sub>50</sub> (μM) <sup>a</sup>		Selectivity
	2'	3'	4'	5'	KB	KB-VIN	KB/KB-VIN	
S4	F			Me	47.3	3.24	15	
S5		Me	F		40.5	1.62	24	

<sup>a</sup>Cytotoxicity as ED<sub>50</sub> values for each cell line, the concentration of compound that caused 50% reduction in absorbance at 562 nm relative to untreated cells using the sulforhodamine B assay.

**Table 3**Activity of **2-4** against Hep3B and Hep3B-VIN

	GI <sub>50</sub> (μM)		
	Hep3B	Hep3B-VIN	Hep3B/Hep3B-VIN
<b>2</b>	47.57	1.57	30
<b>3</b>	7.31	0.35	21
<b>4</b>	6.09	0.72	8.5
paclitaxel	0.0004	16.17	-
vincristine	0.0029	6.86	-